ArticleBMJ open respiratory research2026
Managing pleural infections: a nationwide survey of respiratory physicians in Singapore.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleural infection remains a major cause of morbidity and mortality, with a significant healthcare burden. Despite growing research and guideline recommendations, real-world management continues to vary widely.
methodsAn anonymous cross-sectional survey evaluating current practice was conducted among respiratory physicians across all public hospitals in Singapore. The survey examined key aspects of management, including pleural fluid diagnostics, chest drain management, surgical referral and intrapleural fibrinolytic therapy (IPFT).
results95 respondents (58% response rate) completed the survey. Only 36.8% routinely inoculate pleural fluid into both plain specimen bottles and blood culture bottles, and up to 22% used plain tubes for pH analysis. Opinions on pH-guided chest drain insertion were divided: 50.6% would always consider pH, while 43.1% did not find it useful. IPFT was regarded as first line treatment following failure of standard care (antibiotics and chest drainage) by 63.2%, while 30.5% would only administer IPFT when surgery was deemed unsuitable. Most respondents (81.0%) had used a reduced dose of tissue plasminogen activator, with 12.6% doing so for all patients. The most common reduced dose was 5 mg (73.7%), largely driven by perceived reduction in bleeding risk (64.2%). Once-daily IPFT dosing was reported by 35.8%, primarily due to logistical constraints and safety concerns related to after-hours administration. Management practices, including pleural fluid sampling for microbiology and pH, indication and timing of surgery or IPFT, and IPFT dose adjustment, varied substantially between hospitals and between individual physicians within the same hospital, with no clear association with respondent seniority. Overall key challenges cited included variation in practice (48.4%), limited after-office hours expertise (44.2%) and limited surgical support (37.9%).
conclusionsSignificant variation exists in pleural infection management across Singapore. Strengthening multidisciplinary collaboration, establishing dedicated pleural services and high-quality trials are needed to optimise care pathways.Cite Now.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.